Dr. Reddy’s (RDY) Launches Generic Imitrex

November 24, 2008 8:15 AM EST
Dr. Reddy’s Laboratories (NYSE: RDY) has launched the authorized generic version of GlaxoSmithKline’s (NYSE: GSK) Imitrex (sumatriptan succinate) tablets 25mg, 50mg, and 100mg in the United States. Dr. Reddy’s is the first company to launch an authorized generic version of Imitrex® tablets in the US market.

In October 2006, the Company announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline Imitrex® tablets. The specific financial terms and conditions of the settlement have not been disclosed.

Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company with proven research capabilities. [SM]

You May Also Be Interested In

Related Categories

Corporate News